ADDF Neuroimaging and CSF Biomarker RFP
Funds new biomarkers for Alzheimer's and related dementias through PET ligands, MRI, spinal fluid, and brain activity measures.
Eligibility · Global — open worldwide
The Alzheimer's Drug Discovery Foundation (ADDF) runs the Neuroimaging and CSF Biomarker RFP to develop and validate new diagnostic tools for Alzheimer's disease and related dementias. ADDF has deployed nearly $400 million across 792 programs in 21 countries since 1998 and uses a venture-philanthropy model in which funding is structured as mission-related investments requiring a return tied to sci…
Novel PET ligands, CSF biomarkers, MRI approaches, EEG functional measures. High-priority: neuroinflammation, synaptic integrity, autophagy, TDP-43. Limited interest in amyloid/tau CSF measures.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see the timeline